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It is now widely recognized that the cross-talk between cancer
and stromal cells may play a crucial role in cancer progression.
However, little is known about the complex underlying molecular
mechanisms that occur within the tumor microenvironment. Fi-
broblasts are the major stromal cells with multiple roles, especially
toward both the extracellular matrix and the neighboring cell
population, including neoplastic cells. Consequently, proteomic
analyses would provide a wider resource for a better understanding
of the potential modulating effects exerted by fibroblasts on cancer
cells. In this article we describe the effects of fibroblast stimulation
on the breast cancer cell line (8701-BC) proteomics, using a
trans-well coculture system. Our results clearly indicate that
fibroblasts induce considerable proteomic modulations on 8701-
BC, mainly in the cytoskeleton proteins and glycolytic enzymes.
Additionally, fibroblast-conditioned medium increased neoplastic
cell proliferation and invasion with a concurrent upregulation
of the c-Myc oncogene. Collectively these results suggest that
fibroblast stimulation may enhance the malignant potential of
breast cancer cells in vitro.
Keywords Proteomics; Breast Cancer Cells; Fibroblasts; Invasion
Assay; Cell Proliferation
INTRODUCTION
Breast cancer, as other carcinomas, arises from epithelial
cells through the sequential accumulation of multiple genetic
modifications. Alterations in specific oncogenes and tumor
suppressor genes have been identified and shown to have causal
roles in the initiation, maintenance, and progression of breast
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cancer [1]. This genetic model of tumor progression, however,
has largely ignored the substantial contribution of the tumor
microenvironment to the metastatic phenotype. Indeed, during
the invasion process, neoplastic cells cross the basal lamina
and penetrate the underlying interstitial stroma where they may
interact actively with the host cells [2]. Recent cancer studies
have acknowledged the active roles that tumor stroma can play
in carcinogenesis, focusing on the abnormal communication
between tumor cells and their microenvironment (epigenetic
model) [3–5]. A number of studies have reported that the pro-
liferation and invasiveness of neoplastic cells can be negatively
or positively regulated by the presence of adjacent stromal cells
[6, 7]. Several molecules, such as matrix metalloproteinases,
growth factors, interleukins, chemokines, and collagens, have
been recognized as participants to the tumor-stroma interplay
[8–16], even though the molecular mechanisms underlying these
cross-talks are not yet fully characterized.
In the past few years, the proteomic approach has attracted
great attention because two-dimensional electrophoresis (2D-
IPG), the principal tool in proteomics, is able to resolve
thousands of proteins at the same time. This allows the
study of qualitative and quantitative variations between cells
and tissues under given conditions [17, 18]. The aim of
this study was to investigate the effects of soluble mediators
released by fibroblasts in vitro on breast cancer cells, using
a proteomic-based approach. As a model system we used the
well-characterized breast cancer cell line 8701-BC [19] and
healthy human fibroblasts as effector cells in a coculture system.
The fibroblastic effects on 8701-BC proteomic expression
profiling, occurred as modulations of several classes of proteins,
were identified by N-terminal microsequencing and/or mass
spectrometry analyses. Our results indicate that fibroblast-
derived signals can influence significantly the behavior of 8701-
BC breast cancer cells. Such changes appear to be associated
with the acquisition of a more aggressive cell behavior and
suggest a role of co-actors for fibroblasts during carcinogenesis.
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MATERIALS AND METHODS
Cell Culture
Breast cancer cell line 8701-BC and normal human der-
mal fibroblasts [20] were cultured on Dulbecco’s Modified
Eagle’s Medium (D-MEM) supplemented with 10% fetal calf
serum (FCS; GIBCO), L-glutamine 2 mM, and antibiotics
(100 units/ml penicillin and 100 µg streptomycin) in a
humidified incubator with 5% CO2 in air at 37◦C.
Cell Proliferation Assay
Cell proliferation was determined by the use of a colorimetric
tetrazolium compound (CellTiter 96, Promega). Briefly, 20 µL
of CellTiter 96 was added to 100 µL of medium into each well
containing the cells. After 1 hr of incubation in a humidified,
5% CO2 atmosphere, the absorbance at 492 nm was read using
a 96-well plate reader (Amersham).
Conditioned Medium Preparation
Conditioned medium from confluent fibroblasts was har-
vested after 24 hr culture in D-MEM without serum, centrifuged
to remove cell debris, and sterile filtered.
Coculture Assays
Cocultures of 8701-BC and fibroblasts were performed
utilizing trans-well permeable supports (Costar), with 0.4 µm
pore size membrane. 8701-BC were seeded in the upper wells
at 7.000/cm2, and fibroblasts in the lower wells at 13.000/cm2,
grown separately until sub-confluence and then overlapped for
48 hr without serum. Additional wells containing 8701-BC cells
alone were similarly treated and used as controls.
Protein Extraction from Cell Culture
After washing with ice-cold phosphate buffered saline (PBS),
cells were carefully scraped and incubated on ice for 30 min
with RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40,
0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA) and a
mixture of protease inhibitors (0.01% aprotinin, 10 mM sodium
pyrophosphate, 2 mM sodium orthovanadate, 1 mM PMSF). The
total cellular lysate was centrifuged at 14,000 rpm for 8 min to
clear cell debris, and the supernatant dialyzed against ultrapure
distilled water, lyophilized, and stored at −80◦C until analysis.
Protein concentration in the cellular extracts was determined
using the Bradford method [21].
Two-Dimensional Gel Electrophoresis
Aliquots of the dried cell lysate were solubilized in a
buffer containing 4% CHAPS, 40 mM Tris, 65 mM DTE
(1,4-dithioerythritol), and a trace amount of bromophenol blue
in 8 M urea. The first dimensional separation was performed
at 20◦C on commercial sigmoidal immobilized pH gradient
strips (IPG), 18 cm long with pH range 3.5 to 10 (Pharmacia).
Strips were rehydrated in 8 M urea, 2% CHAPS, 10 mM DTE,
and 0.5% carrier ampholytes (Resolyte 3.5–10). Aliquots of
45 µg (analytical gels) or 90 µg (immunoblot gels) or 1 mg
(preparative gels) of total proteins were applied to the gel strip.
The isoelectrofocusing was carried out by linearly increasing
voltage from 200 to 3500 V during the first 3 hr, after which
focusing was continued at 8000 V for 8 hr.
After the run the IPG strips were equilibrated with a solution
containing 6 M urea, 30% glycerol, 2% SDS, 0.05M Tris-HCl
pH 6.8, and 2% DTE for 12 min, to resolubilize proteins
and reduce disulphuric bonds. The -SH groups were then
blocked by substituting the DTE with 2.5% iodoacetamide in the
equilibrating buffer. The focused proteins were then separated
on 9–16% linear gradient polyacrylamide gels (SDS-PAGE)
with a constant current of 40 mA/gel at 10◦C. Gels were stained
with ammoniacal silver nitrate, digitized using a computing
densitometer, and processed with ImageMaster 2D-Platinum
system (Amersham Biosciences).
N-Terminal Protein Sequencing
N-terminal microsequencing was performed by automated
Edman degradation in a Protein Sequencer (Procise 491,
Applied Biosystems) on protein samples electrotransferred onto
PVDF membranes at 50 V for 30 min at 4◦C. The Swiss-
prot/TrEMBL/BLAST databases were used for online sequence
similarity search at http://www. expasy.ch/tools/#similarity.
Matrix-Assisted Laser Desorption Ionization–Time
of Flight (MALDI-TOF)
Mass spectrometric sequencing was carried out after in-gel
digestion of protein spots, using sequencing-grade trypsin
(20 µg/vial), according to the method of Shevchenko et al.
[22] with some modification. The tryptic peptide extracts
were dried in a vacuum centrifuge and dissolved in 10 µL
of 0.1% trifluoroacetic acid (TFA). The matrix, R-cyano-4-
hydroxycinnamic acid (HCCA), was purchased from Sigma-
Aldrich. A saturated solution of HCCA (1 µL) at 2 mg/200
µL in CH3CN/H2O (50:50 (v/v)) containing 0.1% TFA was
mixed with 1 µL of peptide solution on the MALDI plate
and left to dry. MALDI-TOF mass spectra were recorded on
a Voyager DE-PRO (Applied Biosystems) mass spectrometer,
in the 500–5000 Da mass range, using a minimum of 100 shots
of laser per spectrum. Delayed extraction source and reflector
equipment allowed sufficient resolution to consider MH+ of
monoisotopic peptide masses. Internal calibration was done
using trypsin autolysis fragments at m/z 842.5100, 1045.5642,
and 2211.1046 Da.
Peptide mass fingerprinting was compared to the theoretical
masses from the Swiss-Prot or NCBI sequence databases
using Mascot (http://www.matrixscience.com/). Typical search
parameters were as follows: 50 ppm of mass tolerance, car-
bamidomethylation of cysteine residues, one missed enzymatic
cleavage for trypsin, a minimum of four peptide mass hits was
required for a match, methionine residues could be considered
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90 P. CANCEMI ET AL
in oxidized form, no restriction was placed on the isoelectric
point of the protein, and a protein mass range from 5 to 100 kDa
was allowed.
Western Blotting
For immune detection the gels were electrotransferred onto
nitrocellulose membrane (HyBond ECL, Amersham) at 50 V for
1 hr at 4◦C. After electrotransfer, the membranes were blocked
with 5% of dry milk in T-TBS for 1 hr and probed with one of
the following monoclonal antibodies diluted with 1% milk in
T-TBS: c-MYC, G3P, and PARK7 from Santa Cruz; CK8 from
Chemicon; and VIME from Novocastra. Following incubation
with antimouse peroxidase-linked (Amersham), reaction was re-
vealed using enhanced chemiluminescence (Pierce), according
to the manufacturer’s instructions.
For semiquantitative analyses ECL films were scanned
in a gray scale mode. The pixel density was determined
using ImageQuant TL software (Amersham) after background
subtraction and used to calculate the integrated density of each
selected band. Values of integrated density were reported in
volume units of pixel intensity/cm2. The integrated density for
each band was calculated from three different film expositions.
Cell Migration and Invasion Assay
The invasion efficiency of 8701-BC cells was assayed using
Boyden Chambers with the top side of filters filled with
15 µg Matrigel. For migration, uncoated filters were used.
Fibroblast-conditioned medium or D-MEM medium containing
1 mg/ml of BSA was placed in the lower compartments of
Boyden chambers; 8701-BC cells (150.000 cells) were placed
in the upper compartments and incubated for 6 hr in a humidified
incubator with 5% CO2 in air at 37◦C. Filters were then removed,
fixed in ethanol, and stained with Toluidine blue. The cells
corresponding to the upper filters were wiped off and the cells
that had migrated or invaded through the pores to the lower
side of the filters were counted in a blinded fashion using light
microscopy at 200x magnification. Differences were considered
significant at the ∗p < 0.05 level.
RESULTS AND DISCUSSION
Effect of Fibroblast-Conditioned Medium on 8701-BC
Proliferation
Cell proliferation was determined using the MTS colorimet-
ric assay, at 24, 48, and 96 hr, 5 and 7 days. As shown in
Figure 1A, after 7 days 8701-BC are responsive to fibroblast
stimulation, showing a significant increase of ∼58% with
respect to the control cultures. This time point was chosen for
the proteomic analysis. The increment of proliferation rate was
associated with an increase of ∼45% in the expression of the
oncoprotein c-myc, the most commonly amplified oncogene in
human breast cancer [23] involved in the control of cellular
growth [24]. Figure 1B shows a prototype of Western blot
(WB) assay for c-Myc and PARK7 expression in control and
cocultured cells, run on the same gel. PARK7 protein was
used as loading control, because of its unchanged proteomic-
expression levels between control and cocultured cells.
Figure 1C shows the relative quantification of the WB den-
sitometric values of c-Myc normalized to the PARK7 protein
expression level.
Effect of Coculture on Protein Expression Profiles
of 8701-BC
Figure 2 shows the miniatures of the proteomic maps of 8701-
BC control and coculture. The protein identities are marked
with labels corresponding to the abbreviated name of Swiss-
Prot database. One hundred sixty protein spots, corresponding
to 97 distinct proteins, were identified in the maps. The
protein identity was assessed by N-terminal sequencing and
by MALDI-TOF. The identified proteins are grouped into 11
functional categories, according to our previously described
criteria [17, 25, 26]: cytoskeleton and associated proteins,
metabolic enzymes, molecular chaperones/heat shock proteins,
membrane-associated proteins with multiple activities, calcium-
binding proteins, proteins with binding function, biosynthesis
and proliferation regulators, protein degradation, detoxification
and redox proteins, proteins with extracellular activity, and
signal transduction. The supplementary Table 1 reports the
identified protein spots, displayed according to their functional
category.
To compare the pattern and intensity of protein expression
between 8701-BC control and cocultured cells, we carried
out triplicate experiments to ensure reproducibility of results,
and we applied the densitometric algorithm of the Image
Master software, normalizing the data to the sum of all spot
volumes on gels (% vol) [27, 28]. The quantitative analysis was
performed on the 161 identified protein spots. According to
our previously described criteria for gene expression amplitude,
the degree of the modulation was considered high (∗∗) for fold
values ≥2 and medium (∗) for values between 2.0 and 1.5
[29].
Figure 3 displays the diagram of protein fold variation
expressed in a logarithm scale and sorted by functional cate-
gories. The 77% of selected proteins showed no variation, while
23% were modulated, either positively (12%) or negatively
(11%). In the group of cytoskeleton and associated proteins
we identified 31 protein spots corresponding to 14 different
proteins. Three of them, and their isoforms, are structural
components of the cytoskeleton: actin, tubulin, and keratin.
Furthermore, the identification of cytokeratin 8 (a marker of
normal lumenal mammary cells) and vimentin (a marker for
epithelium-mesenchymal transition) was performed by Western
blot analyses, as reported below. The majority of the other
proteins in this group correspond to actin-binding proteins
(cofilin, ezrin, myosin light chain 6, profilin-1, tropomyosin,
and thymosin).
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FIBROBLASTS EFFECT ON BREAST CANCER PHENOTYPE 91
FIG. 1. (A) Diagram illustrates the growth rate of 8701-BC cells cultured in the presence (dotted line) or absence (continuos line) of fibroblast medium using
the MTS colorimetric assay. Fibroblast stimulation induce a cell increament of 58% at 7 days vs. control cells. Each time point represents the mean of 3 replicates
from three independent experiments (± SD). (B) A prototype of 3 replicate Western blot (WB) assays for c-Myc and PARK7 protein expression in control and
cocultured cells run on the same gels. (C) Diagram shows the relative quantification of the WB densitometric values of c-myc normalized to the PARK7 protein
expression level.
Responsive proteins, defined as positive or negative modu-
lations, corresponded to 11 of the 31 identified in this group.
High levels of modulation were detected for tropomyosin 3, one
isoform of profilin 1, 1 isoform of tropomyosin 2 and myosin
light polypeptide 6. Moderately increased levels were detected
for 3 actin isoforms, while moderately-decreased levels were
found for one isoform of tropomyosin 4, for thymosin B4 and
for 2 actin isoforms.
Most modulated proteins included the tropomyosin com-
ponents. Tropomyosins are composed of alpha helix-subunits,
which assemble into parallel homo- or heterodimeric coiled-coil
structures. In human, the tropomyosins are coded by four
homologue genes, TPM1, TPM2, TPM3, and TPM4, which may
also generate a number of isoforms due to alternative splicing.
Literature evidence suggests that selected combinations of these
isoforms play important roles for actin cytoskeleton functions,
such as cellular vesicle traffic, cell proliferation and apoptosis,
and cell migration [30].
Interestingly, our results show different responses induced by
fibroblastic stimulation on the tropomyosins subunits. Indeed,
tropomyosin 1 was not modulated, whereas tropomyosin 2
and tropomyosin 3 were upregulated and tropomyosin 4 was
downregulated.
The category of metabolic enzymes contains 36 spots, corre-
sponding to 17 different enzymes and isoforms. Eight of these
belong to the anaerobic glycolytic pathway, 4 are mitochondrial
enzymes of the aerobic pathways, and the others (acyl-coA de-
hydrogenase, retinal dehydrogenase, enoyl-coA hydratase, and
N(G),N(G)-dimethylarginine dimethylaminohydrolase) belong
to other metabolic pathways. Interestingly the majority of the
proteins belonging to the glycolytic pathway (glyceraldehyde-
3-phosphate (G3P) dehydrogenase, triosephosphate isomerase,
phosphoglycerate kinase 1) were upregulated, suggesting that
the fibroblast-induced increment of cell proliferation is ac-
companied by a more marked metabolic shift toward glycol-
ysis.
Due to the elevated number of different isoforms detected
for G3P, Western blot analysis was performed on 2D gels,
confirming the silver stained pattern of these protein isoforms
(Figure 4). The observed increase of the glycolytic enzyme ex-
pression is concordant with the increment of c-Myc expression,
which is known to activate (directly or indirectly) a number of
genes related to the glycolytic pathway [31, 32]. The elevated
levels of anaerobic metabolism, even in the presence of oxygen,
known as the “Warburg effect,” is a frequent clinical syndrome
in oncologic patients, an observation recognized by several
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92 P. CANCEMI ET AL
FIG. 2. Representative proteomic maps of 8701-BC control cells and cocultured with fibroblasts. 2-DE separation was performed on IPG gel strips (18 cm,
3.5–10 NL) followed by the SDS-Page on a vertical linear-gradient slab gel (9–16%T). Protein spots of known identity are labeled with the abbreviated name of
the Swiss-Prot/TrEMBL database. When present, different isoforms of the same protein are jointly labeled. sf = short form; Fr = fragment.
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TABLE 1
Proteins identified on the 8701-BC proteome
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Cytoskeleton and associated proteins
Actin, cytoplasmic 1/2 P60709/P63261 ACTB/G 5.13 42000 1,3 7/19 (36%) 22
(5.29) (41736)
Actin, cytoplasmic 1/2 P60709/P63261 ACTB/G 5.16 42000 1,3 7/21 (33%) 23
Actin, cytoplasmic 1/2 P60709/P63261 ACTB/G 5.20 42000 1,3 8/56 (14%) 31
Actin, cytoplasmic 1/2 P60709/P63261 ACTB/G 5.23 42000 1,3 9/20 (45%) 41
Actin, cytoplasmic
1/2 (fr)
P60709/P63261 ACT (fr) 5.43 40685 1 7/23 (30%) 26
Actin, cytoplasmic
1/2 (fr)
P60709/P63261 ACT (fr) 5.38 33856 2 res.62–71
Actin, cytoplasmic
1/2 (fr)
P60709/P63261 ACT (fr) 5.24 26622 1 12/87 (14%) 50
Actin, cytoplasmic 2 P63261 ACTG 5.43 35000 1 9/18 (50%) 31
(5.31) (41793)
Cofilin-1 P23528 COF1 5.87 15657 1 9/20 (45%) 61
(8.26) (18371)
Ezrin P15311 EZRI 6.05 75207 1 19/25 (76%) 24
(5.95) (69268)
Keratin, type I
cytoskeletal 9
P35527 K1C9 5.27 44881 1 4/22 (18%) 11
(5.14) (61987)
Myosin light
polypeptide 6
P60660 MYL6 4.43 14537 1 10/17(58%) 60
(4.56) (16799)
Profilin-1 P07737 PROF1 6.97 12118 1 5/24 (21%) 40
(8.47) (14923)
Profilin-1 P07737 PROF1 7.40 12217 1 7/8 (87%) 60
Tubulin alpha-1 chain P68366 TBA1 5.10 54581 1 19/33 (57%) 51
(4.95) (49924)
Tubulin alpha-1 chain P68366 TBA1 5.11 54220 1 13/17 (76%) 52
Tubulin alpha-1 chain P68366 TBA1 5.10 53152 1 8/14 (57%) 30
Tubulin beta-5 chain P07437 TBB5 4.95 50909 1 30/57 (52%) 58
(4.78) (49671)
Tubulin beta-5 chain P07437 TBB5 4.98 50740 1 21/25 (84%) 60
Tubulin beta-5 chain P07437 TBB (fr) 5.15 36502 2 res. 2–10
Tubulin beta-5 chain P07437 TBB (fr) 5.26 36502 2 res. 2–10
Tubulin beta-5 chain P07437 TBB (fr) 4.90 11502 2 res. 2–10
Tropomyosin alpha-1
chain
P09493 TPM1 4.91 32894 1 17/79 (21%) 36
(4.69) (32709)
Tropomyosin beta
chain
P07951 TPM2 4.80 43127 1 11/29 (37%) 22
(4.66) (32851)
Tropomyosin beta
chain
P07951 TPM2 4.78 36982 4
Tropomyosin alpha 3
chain
P06753 TPM3 4.90 31938 1 11/26 (42%) 27
(4.68) (32818)
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Tropomyosin alpha-4
chain
P67936 TPM4 4.77 36110 1 18/44 (40%) 43
(4.67) (28391)
Tropomyosin alpha-4
chain
P67936 TPM4 4.79 32869 4
Thymosin beta-4 P62328 TYB4 4.79 11252 4
(5.02) (4921)
Vinculin P18206 VINC 5.56 119845 1 23/146 (16%) 26
(5.50) (123799)
Vinculin P18206 VINC 5.70 119845 1 29/118 (25%) 30
Metabolic enzymes
Aconitate hydratase,
mitochondrial
Q99798 ACON 6.93 84876 1 17/29 (58%) 22
(7.36) (85425)
Retinal
dehydrogenase 1
P00352 AL1A1 6.80 50405 1 21/34 (61%) 49
(6.29) (54731)
(fr)uctose-
bisphosphate
aldolase A
P04075 ALDOA 5.27 38975 1 15/24 (62%) 59
(8.39) (39289)
(fr)uctose-
bisphosphate
aldolase A
P04075 ALDOA 7.34 38913 1 4/10 (40%) 20
ATP synthase subunit
beta, mitochondrial
P06576 ATPB 5.05 50405 1 31/35 (88%) 59
(5.26) (56560)
N(G),N(G)-
dimethylarginine
dimethylaminohy-
drolase 1
O94760 DDAH1 5.35 36806 1 13/49 (27%) 56
(5.53) (31122)
N(G),N(G)-
dimethylarginine
dimethylaminohy-
drolase 2
O95865 DDAH2 5.39 27625 1 6/22 (27%) 35
(5.66) (29644)
Enoyl-CoA hydratase,
mitochondrial
P30084 ECHM 5.62 25751 2 res 28–37
(8.34) (31387)
Alpha-enolase P06733 ENOA 6.03 47404 3
(6.99) (47037)
Alpha-enolase P06733 ENOA 6.28 47225 3
Alpha-enolase P06733 ENOA 6.56 47225 3
Alpha-enolase P06733 ENOA 6.84 47225 3
Alpha-enolase (sf) P06733 ENOA (sf) 5.59 38543 1 13/43 (30%) 35
Alpha-enolase (sf) P06733 ENOA (sf) 6.79 41010 2 res 57–66
Glyceraldehyde-3-
phosphate
dehydrogenase
P04406 G3P 7.09 36053 2 res 2–7
(8.58) (35922)
(Continued on next page)
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Glyceraldehyde-3-
phosphate
dehydrogenase
P04406 G3P 7.27 36110 2 res 2–11
Glyceraldehyde-3-
phosphate
dehydrogenase
P04406 G3P 7.39 36110 2 res 2–21
Glyceraldehyde-3-
phosphate
dehydrogenase
P04406 G3P 7.44 36053 2 res 2–11
Glyceraldehyde-3-
phosphate
dehydrogenase
P04406 G3P 7.52 36053 2 res 2–31
Pyruvate kinase
isozymes M1/M2
P14618 KPYM 7.03 61773 1 17/68 (25%) 39
(7.95) (57805)
Pyruvate kinase
isozymes M1/M2
P14618 KPYM 7.11 62478 1 25/28 (89%) 53
L-lactate dehydrogenase
A chain
P00338 LDHA 7.35 33982 1 8/23 (34%) 36
(8.46) (36558)
L-lactate dehydrogenase
B chain
P07195 LDHB 5.43 36053 1 15/30 (50%) 48
(5.72) (36507)
Malate dehydrogenase,
cytoplasmic
P40925 MDHC 6.70 36053 1 12/54 (22%) 37
(8.92) (35831)
Malate dehydrogenase,
mitochondrial
P40926 MDHM 7.41 34807 1 12/13 (92%) 50
(8.92) (35531)
Phosphoglycerate
mutase 1
P18669 PGAM1 6.46 26524 1 11/28 (39%) 51
(6.75) (28673)
Phosphoglycerate
mutase 1
P18669 PGAM1 6.77 26524 1 14/29 (48%) 58
Phosphoglycerate
kinase 1
P00558 PGK 1 7.08 41933 1 5/19 (26%) 17
(8.30) (44483)
Phosphoglycerate
kinase 1
P00558 PGK 1 7.25 42000 4
Phosphoglycerate
kinase 1
P00558 PGK 1 7.36 42000 1 5/16 (31%) 24
Triosephosphate
isomerase
P60174 TPIS 4.90 25581 1 10/15 (66%) 55
(6.51) (26538)
Triosephosphate
isomerase
P60174 TPIS 5.47 22390 2 res 49–58
Triosephosphate
isomerase
P60174 TPIS 6.40 25000 2 res.1–9
Triosephosphate
isomerase
P60174 TPIS 6.63 24921 2 res.3–11
Triosephosphate
isomerase
P60174 TPIS 6.81 25000 2 res.2–6
Triosephosphate
isomerase (sf)
P60174 TPIS (sf) 5.82 22035 2 res.49–58
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Molecular chaperones/Heat shock proteins
Calreticulin P27797 CALR 4.52 62007 1 21/168 (12%) 58
(4.29) (48142)
75 kDa glucose-
regulated protein
P38646 GRP75 5.30 73791 1 14/17 (82%) 24
(5.87) (73681)
78 kDa glucose-
regulated protein
P11021 GRP78 4.97 75771 4
(5.07) (72333)
78 kDa glucose-
regulated protein
P11021 GRP78 5.01 76058 1 28/42 (66%) 49
78 kDa glucose-
regulated protein
P11021 GRP78 5.04 76058 1 13/17 (76%) 25
94 kDa glucose-
regulated protein
P14625 GRP94 4.90 91200 4
(4.76) (92469)
Heat shock protein
beta-1
P04792 HSP27 5.43 24530 1 6/22 (27%) 29
(5.98) (22783)
Heat shock protein
beta-1
P04792 HSP27 5.54 24569 1 12/39 (31%) 52
Heat shock protein
beta-1
P04792 HSP27 5.55 24031 1 12/23 (52%) 61
60 kDa heat shock
protein,
mitochondrial
P10809 HSP60 5.19 61773 4
(5.27) (59500)
60 kDa heat shock
protein,
mitochondrial
P10809 HSP60 5.24 62007 2 res 33–38
60 kDa heat shock
protein,
mitochondrial
P10809 HSP60 5.23 59500 2 res 33–38
60 kDa heat shock
protein,
mitochondrial
P10809 HSP60 5.27 59500 1, 2 15/19 (78%) res 33–38
39
Heat shock 70 kDa
protein 1
P08107 HSP71 5.33 70251 4
(5.48) (70052)
Heat shock 70 kDa
protein 4
P34932 HSP74 5.12 110395 1 10/17 (58%) 18
(5.18) (94300)
Heat shock cognate 71
kDa protein
P11142 HSP7C 5.27 71322 1 24/34 (70%) 43
(5.38) (70898)
Heat shock cognate 71
kDa protein
P11142 HSP7C 5.34 73791 1 19/50 (38%) 38
Parkinson disease
protein 7-Oncogene
DJ1
Q99497 PARK7 5.79 21164 1 11/41 (27%) 66
(6.33) (19891)
Protein
disulfide-isomerase
P07237 PDIA1 4.85 59480 1 4/12 (33%) 9
(4.76) (57117)
Protein disulfide-
isomerase A3
P30101 PDIA3 5.45 55566 1 11/19 (57%) 21
(5.9) (56783)
(Continued on next page)
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Protein disulfide-
isomerase A3
P30101 PDIA3 5.50 54939 1 11/19 (57%) 27
Peptidyl-prolyl cis-trans
isomerase A
P62937 PPIA 6.25 14758 1 6/29 (21%) 56
(7.82) (17881)
Peptidyl-prolyl cis-trans
isomerase A
P62937 PPIA 6.65 14389 4
Peptidyl-prolyl cis-trans
isomerase A
P62937 PPIA 7.02 14552 1 14/19 (73%) 65
Peptidyl-prolyl cis-trans
isomerase A
P62937 PPIA 7.18 14511 1 8/24 (33%) 51
T-complex protein 1
subunit zeta
P40227 TCPZ 6.43 58908 4
(6.25) (57893)
Translationally
controlled tumor
protein
P13693 TCTP 4.91 19559 4
(4.84) (19595)
Transitional
endoplasmic
reticulum ATPase
P55072 TERA 5.18 89154 1 19/28 (67%) 40
(5.14) (89191)
Membrane-associated proteins with multiple activities
Annexin A1 P04083 ANXA1 6.73 36748 1 7/10 (70%) 33
(6.64) (38583)
Annexin A1 P04083 ANXA1 (sf) 7.04 30801 2 res 12–21
Annexin A1 P04083 ANXA1 (sf) 7.34 27933 2 res 26–35
Annexin A2 P07355 ANXA2 7.06 36053 1 5/12 (66%) 28
(7.56) (38473)
Annexin A2 P07355 ANXA2 6.85 35500 1 5/10 (50%) 15
Annexin A2 P07355 ANXA2 (sf) 6.83 30855 1 12/22 (54%) 30
Annexin A4 P09525 ANXA4 5.25 32135 1 7/7 (100%) 26
(5.85) (35752)
Annexin A4 P09525 ANXA4 5.53 31938 1 12/16 (75%) 36
Galectin-1 P09382 LEG1 4.93 11616 1 7/16 (43%) 52
(5.34) (14584)
Galectin-1 P09382 LEG1 5.06 11486 1 5/17 (29%) 34
Galectin-3 P17931 LEG3 7.33 26426 4
(8.60) (26057)
Galectin-3 P17931 LEG3 7.49 26524 1 8/17 (47%) 26
Voltage-dependent
anion-selective
channel protein 1
P21796 VDAC1 7.41 31017 4
(8.63) (30641)
Voltage-dependent
anion-selective
channel protein 1
P21796 VDAC1 7.56 31393 1 13/17 (76%) 73
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Calcium binding proteins
Calmodulin P62158 CALM 4.36 12118 1 6/20 (30%) 54
(4.09) (16706)
Protein S100-A4 P26447 S10A4 5.39 9352 1 6/16 (37%) 45
(5.85) (11729)
Protein S100-A6 P06703 S10A6 4.96 8790 1 3/16 (18%) 26
(5.32) (10180)
Protein S100-A6 P06703 S10A6 5.09 8765 4
Protein S100-A11 P31949 S10AB 5.55 9728 1 5/11 (45%) 42
(6.56) (11740)
Proteins with binding functions
Fatty acid-binding
protein, epidermal
Q01469 FABP5 5.91 11948 1 8/23 (34%) 52
(6.60) (15164)
Phosphatidylethanol-
amine-binding
protein 1
P30086 PEBP1 6.88 19123 2 res. 1–10
(7.43) (20965)
Cellular retinoic
acid-binding
protein 2
P29373 RABP2 5.35 12118 2 res. 1–10
(4.73) (27745)
Complement
component 1 Q
subcomponent-
binding protein,
mitochondrial
Q07021 C1QBP 4.54 31231 2 res 74–84
(4.74) (31362)
Complement
component 1 Q
subcomponent-
binding protein,
mitochondrial
Q07021 C1QBP 4.54 30855 1 7/32 (22%) 40
Biosynthesis and
proliferation
regulators
Acidic leucine-rich
nuclear
phosphoprotein 32
family member A
P39687 AN32A 4.15 28703 1 10/35 (29%) 30
(3.99) (28585)
Elongation factor
1-beta
P24534 EF1B 4.65 30413 1 10/10 (100%) 46
(4.50) (24632)
Elongation factor Tu,
mitochondrial
P49411 EFTU 6.52 44881 2 res 44–52
(5.38) (36502)
Eukaryotic translation
initiation factor 3
subunit 2
Q13347 IF32 5.44 36502 1 13/45 (28%) 52
(5.38) (36502)
Eukaryotic translation
initiation factor 5A
P63241 IF5A 5.08 14897 1 12/31 (38%) 67
(5.08) (16701)
(Continued on next page)
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TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Nucleoside diphosphate
kinase A
P15531 NDKA 5.49 17673 1 8/37 (21%) 52
(5.83) (17149)
Nucleoside diphosphate
kinase B
P22392 NDKB 7.52 15613 1 10/17 (58%) 56
(8.52) (17298)
Nucleophosmin P06748 NPM 4.92 38913 1 8/15 (53%) 28
(4.64) (32675)
Nucleophosmin (fr) P06748 NPM (fr) 4.46 16963 1 6/10 (60%) 23
Nuclear transport
factor 2
P61970 NTF2 4.95 10437 1 7/19 (37%) 53
(5.10) (14478)
Prohibitin P35232 PHB 5.35 25186 1 9/16 (56%) 58
(5.57) (29804)
39S ribosomal protein
L12
P52815 RM12 5.09 19355 4
(9.05) (21348)
Heterogeneous nuclear
ribonucleoproteins
A2/B1
P22626 ROA2 6.59 17426 1 15/122 (12%) 31
(8.97) (37429)
SH3 domain-binding
glutamic
acid-rich-like protein
O75368 SH3L1 5.23 11918 2 res. 2–11
(5.22) (12643)
Thymidine
phosphorylase
P19971 TYPH 5.23 52105 1 6/8 (75%) 20
Protein degradation (5.36) (49955)
Proteasome subunit
alpha type-5
P28066 PSA5 4.76 25751 2 res. 4–13
(4.74) (26411)
Ubiquitin P62988 UBIQ 6.87 8594 2 res. 1–15
(5.56) (8583)
Ubiquitin
carboxyl-terminal
hydrolase isozyme L1
P09936 UCHL1 5.30 24414 1 10/14 (71%) 67
(5.33) (24824)
Detoxification and redox proteins
Aldo-keto reductase
family 1 member A1
P14550 AK1A1 6.47 38299 1 7/20 (35%) 28
(6.32) (36573)
Aldo-keto reductase
family 1 member B10
O60218 AK1BA 6.90 35289 1 6/14 (42%) 25
(7.12) (36021)
Aldo-keto reductase
family 1 member B10
O60218 AK1BA 6.99 35500 1 7/18 (38%) 36
Aldo-keto reductase
family 1 member C3
P42330 AK1C3 7.23 35652 1 — 30
(8.05) (36844)
Aldose reductase P15121 ALDR 6.40 35920 1 3/10 (30%) 21
(6.55) (35722)
Aldose reductase P15121 ALDR 6.57 36053 1 8/14 (57%) 41
Carbonic anhydrase 1 P00915 CAH1 6.89 27946 1 13/78 (17%) 65
(6.63) (28870)
Glutathione
S-tran(sf)erase P
P09211 GSTP1 5.36 23356 2 res 1–10
(5.44) (23225)
Co
nn
ec
t T
iss
ue
 R
es
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
ET
H
 Z
ue
ric
h 
on
 0
5/
02
/1
2
Fo
r p
er
so
na
l u
se
 o
nl
y.
100 P. CANCEMI ET AL
TABLE 1
Proteins identified on the 8701-BC proteome (Continued)
Protein name AC number
Abbreviated
Name
Exp. pI
(theoretical)
Exp.Mr
(theoretical)
ID
methods
% masses
matched
Sequence
coverage
(%)
N-terminal
residues
Peroxiredoxin-1 Q06830 PRDX1 6.76 20518 1 14/133 (11%) 73
(8.27) (22110)
Peroxiredoxin-1 Q06830 PRDX1 7.07 22771 1 7/11 (63%) 45
Peroxiredoxin-1 Q06830 PRDX1 7.34 23094 1 14/19 (73%) 55
Peroxiredoxin-2 P32119 PRDX2 5.11 18803 1 10/55 (18%) 36
(5.66) (21891)
Peroxiredoxin-4 Q13162 PRDX4 5.68 25581 1 13/145 (9%) 57
(5.86) (30540)
Peroxiredoxin 6 P30041 PRDX6 5.67 26680 1 8/15 (53%) 34
(6.02) (24904)
Superoxide dismutase
[Cu-Zn]
P00441 SODC 5.43 15924 1 6/27 (22%) 73
(5.70) (15804)
Superoxide dismutase
[Cu-Zn]
P00441 SODC 6.91 22264 2 res. 25–34
Superoxide dismutase
[Mn], mitochondrial
P04179 SODM 6.72 20760 4
(8.35) (24722)
Superoxide dismutase
[Mn], mitochondrial
P04179 SODM 6.88 20634 1 8/16 (50%) 50
Thioredoxin P10599 THIO 4.97 11230 2 res 1–10
(4.82) (11606)
Proteins with extracellular activity
Cathepsin D P07339 CATD 5.27 28560 1 17/44 (39%) 41
(5.56) (26628)
Macrophage Migration
Inhibitory Factor
P14174 MIF 7.30 11350 1 4/20 (20%) 23
(8.24) (12345)
Signal transduction
Rho GDP-dissociation
inhibitor 1
P52565 GDIR 5.02 23430 1 7/31(23%) 38
(5.03) (23207)
Rho GDP-dissociation
inhibitor 2
P52566 GDIS 5.09 22643 1 11/39 (28%) 64
(5.10) (22988)
ID Methods: 1 Maldi; 2 Nt-microsequencing; 3 Western Blot; 4 Gel matching with our previous published maps.
authors, including our group [17, 25, 26], as a frequent feature
of neoplastic cells both in vivo and in vitro.
It is also note worthy that the enzyme retinal dehydrogenase
(ALIA1), which is a breast cancer stem cell marker, remains
unchanged after fibroblast stimulation. This further suggests
that, in this context, fibroblasts are unable to revert the malignant
phenotype of breast cancer cells 8701-BC.
Within the group of molecular chaperones/heat shock
proteins we detected 28 spots corresponding to 16 proteins.
Generally, heat shock protein (HSP) levels increase under
conditions of cellular stress to provide cellular protection and
maintain homeostasis. HSPs act as “molecular chaperones,” by
assisting protein folding, transport, and degradation. But during
stress, they prevent aggregation and promote the refolding
of damaged proteins. Surprisingly, only one protein form,
protein disulfide-isomerase 3 (PDIA3), was found significantly
upregulated in coculture, while 5 proteins of this category
decreased their expression and the others remained unaffected,
suggesting that fibroblastic effects on neoplastic cells do not
drive stress-related activities.
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FIG. 3. Diagram presents protein fold variation between cocultured and control cells, expressed in a logarithm scale and sorted by functional categories alphabetic
letters after the protein names indicate the isoelectric forms (when present) from more acidic (a) to more basic pH. Relative intensity of protein spots was calculated
normalizing the data to the sum of all spot volumes on gels (vol%). Each value is the mean of three independent determinations. For graphical limitations the SD
values (5–10%) were not included in this figure. According to general criteria for gene expression amplitude, the degree of the modulation was considered high
(∗∗) for fold values ≥ 2 and medium (∗) for values between 2.0 and 1.5.
The disulfide-isomerase protein is a multifunctional chaper-
one present both in the cytosol and at the cell surface where
it mediates integrin-dependent cell adhesion [33]. Interestingly,
PDI was identified to play an important role in glioma cell
invasion [34]. To our knowledge this is the first report suggesting
that fibroblasts may enhance PDI in cancer cells, possibly
potentiating their invasive behaviour.
Membrane-associated proteins with multiple activities in-
clude the annexins, galectins, and the voltage-dependent anion-
selective channel protein 1. Among this group, galectin-1,
annexin A2, and a short form of it (ANX2LC) were found
increased in the cocultured cells, while annexin A1 showed
decreased expression. Annexin A2 is a ubiquitous Ca2+-binding
protein shown to be involved in several cellular processes such as
cell motility and actin-dependent vesicle transport. In general it
has an essential role in maintaining the plasticity of the dynamic
membrane-associated actin cytoskeleton [35]. Conversely, the
FIG. 4. 2D-Western blot shows different isoforms of G3P detected in the
proteomic maps.
decrease of Annexin A1, which is mainly involved in oxidative
stress responses and apoptosis, may be related to the observed
attenuation of HSP expression levels [36].
One other category of interest is that of the calcium binding
proteins, including calmodulin and some protein forms of the
S100 protein family (protein S100-A11, 2 isoforms of S100
calcium-binding protein A4, and 2 isoforms of S100 calcium-
binding protein A6). These were generally unchanged, except
S10A6 which appeared downregulated, as reported by other
authors in different types of tumor [37, 38].
The class of detoxification and redox proteins included
several enzymatic forms and isoforms, most of which remained
unchanged in the cocultured cells. However, the superoxide
dismutase (SODM) was upregulated, while other members
such as aldo-keto reductase family 1 member B10, aldose
reductase (2 isoforms), aldo-keto reductase family 1 member
C3, and thioredoxin had decreased expression. These responses
reflect the complexity of the metabolic dynamism of cells under
external influences.
Concerning the other protein categories, a limited number
of proteins were influenced by the fibroblastic stimuli. Among
these, elongation factor 1-beta and nucleophosmin were down-
regulated, while the macrophage migration inhibitory factor was
upregulated together with proteasome subunit beta type-4.
Effect of Coculture on Expression of Cytoskeletal Proteins
CK 8 and Vimentin
Following the proteomic analyses, which revealed that the
cytoskeleton and associated proteins (36% of identified spots)
were mostly responsive to the coculture event, we examined
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FIG. 5. Panel of Western blots for the immune detection of cytokeratin-8 and vimentin on 8701-BC control cells and cocultured with fibroblasts both in 1-D
electrophoresis (A) and 2D electrophoresis (B). Each image of B represents the experimental windows of the Western blot matched with the corresponding silver
stained gels for the attribution of pI/Mr coordinates. The position of beta-actin is reported for reference. (C) Influence of fibroblast medium on migration and
invasion of 8701-BC cells. The ability of cells to migrate through the filter was assayed in the absence and invasion in the presence of a Matrigel layer. The data
plotted are the means ± SD for 3 wells in triplicate experiments under the different conditions. ∗p < 0.05.
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the occurrence of cytokeratin 8 and vimentin, which are
molecular markers for epithelial and mesenchymal phenotype,
respectively, and used in diagnostic histopathology [39–41]. As
shown in Figure 5A, there is a general decrement of CK8 im-
munostaining and a concomitant increment of vimentin forms,
following fibroblast stimulation. Bidimensional detection of
both proteins revealed the presence of several isoforms for each
protein and confirmed a net decrement for the CK8 forms and
concurrent increment of vimentin isoforms (Fig. 5B). These
results strongly suggest the occurrence of an accentuation of
epithelial-mesenchymal transition of 8701-BC cocultured with
fibroblasts [42, 43].
Fibroblast-Conditioned Medium Effects on 8701-BC
Invasion
To verify if fibroblast effects on intermediate filament
transition could also enhance the locomotory and invasive
behavior of 8701-BC cells, we performed both migration
and matrigel invasion assays, using the Boyden Chamber
system. The results obtained (Fig. 5C) clearly demonstrate that
fibroblasts significantly increase the invasive potential of the
breast cancer cells 8701-BC.
CONCLUSIONS
There is growing evidence that interactions between tu-
mor cells and the surrounding stromal tissue and cells play
a critical role in tumor growth, invasion, metastasis, and
angiogenesis. The recruitment of the fibroblasts around the
primary site of many tumors has been assigned important roles
for carcinogenesis. However, to our knowledge the possible
influences of fibroblasts on neoplastic cell behavior have not
been exhaustively explored, and there is little information
presently available at the proteomic level.
Our report provides the first evidence for multiple effects
of fibroblastic stimulation on breast cancer cells, including
proteomics, proliferation, and invasion assays. Cell proliferation
assays showed a significant increase of growth rate of 8701-
BC cells in response to fibroblastic stimulation. Comparative
proteomic analyses of control and cocultured cells revealed
significant upregulation of several glycolytic enzymes (G3P,
TPIS, PGK1). It is well recognized that enhanced glycolytic
metabolism, in part due to the upregulation of c-Myc, represents
an adaptation to environmental parameters which favors invasive
properties of the cancer cells [44], as successfully verified by
Boyden chamber migration and invasion assays.
Moreover, the remarkable modulations of proteins belonging
to the functional category of cytoskeleton and associated
proteins, suggest a dynamic remodelling of the cytoskeleton
of cocultured cells, which in turn may be responsible of mi-
gratory and invasiveness activities. In fact, conditioned medium
produced by fibroblasts successfully stimulated motility and
invasion of breast cancer cells, as other authors have previously
demonstrated [45].
Interestingly, the categories of molecular chaperones and
detoxification were the only two groups which collectively
underwent downregulation. They play a fundamental role in
the maintenance of cellular homeostasis. In our system, this
downregulation suggests an antistress or cytoprotective effect by
the fibroblastic factors on breast cancer cells. This is supported
by the overexpression of SOD, which might protect cells from
toxic damage and induce a pro-survival response.
In conclusion, our present results suggest that epigenetic
stimulation mediated by fibroblastic factors enhances the
invasive activities of breast cancer cells through cytoskeleton
modulation, altered metabolism, increased rate of cell prolifer-
ation, migration, and invasive capabilities.
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